Effect of treatment plan quality on outcomes after radiosurgery for vestibular schwannoma.

J Neurosurg

Department of Neurosurgery, University of Florida, Gainesville, Florida 32610, USA.

Published: November 2007

Object: The goal in this study was to review the effects of treatment plan quality on outcomes after radiosurgery for vestibular schwannoma (VS).

Methods: Between July 1988 and August 2005, 390 patients were treated. The results of this experience have been published recently. In this study the authors looked at dosimetry variables: conformity of treatment plan and steepness of dose gradient, in the same group of patients. Over the duration of this study, dosimetry evolved from a single isocenter with marginal conformity to multiple isocenters with high conformity. Multivariate statistics were used to determine the effects of these variables on tumor control and on two types of complication, facial weakness and facial numbness.

Results: The 5-year actuarial tumor control was 91%. Dosimetry had no effect on tumor control. Eighteen patients (4.6%) reported new-onset facial weakness and 14 (3.6%) reported new-onset facial numbness. Since 1994, when peripheral treatment doses were lowered to 1250 cGy, only three (1%) of 298 patients have experienced facial weakness and two (0.7%) of 298 have experienced facial numbness. Statistical analysis confirms, as in the prior study, that treatment volume and treatment dose are significant predictors of both facial weakness and facial numbness. In this model, prior tumor growth was also significant. Dosimetry, however, is definitely not a significant predictor of either complication.

Conclusions: Treatment dose appears to be much more important than treatment plan quality in the prevention of facial numbness or weakness after radiosurgery for VS.

Download full-text PDF

Source
http://dx.doi.org/10.3171/JNS-07/11/0913DOI Listing

Publication Analysis

Top Keywords

treatment plan
16
facial weakness
16
facial numbness
16
plan quality
12
tumor control
12
facial
9
treatment
8
quality outcomes
8
outcomes radiosurgery
8
radiosurgery vestibular
8

Similar Publications

Global phylogeography and genetic characterization of carbapenem and ceftazidime-avibactam resistant KPC-33-producing Pseudomonas aeruginosa.

NPJ Antimicrob Resist

January 2025

Laboratory Medicine Center, Department of Clinical Laboratory, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, 310014, China.

Ceftazidime-avibactam (CZA) is currently one of the last resorts used to treat infections caused by carbapenem-resistant Enterobacteriaceae and Pseudomonas aeruginosa. However, KPC variants have become the main mechanism mediating CZA resistance in KPC-producing gram-negative bacteria after increasing the application of CZA. Our previous study revealed that CZA-resistant KPC-33 had emerged in carbapenem-resistant P.

View Article and Find Full Text PDF

Hepatocyte growth factor (HGF) is a substance that stimulates the proliferation of hepatocytes which promote healing. We developed a macrophage membrane-encapsulated nanosphere drug delivery system containing HGF for the study of burn wound healing. Twenty-seven Sprague-Dawley rats were randomly divided into three groups: a saline control (NS) group, an engineered macrophage membrane-encapsulated nanospheres (ETMM@NPS) group, and an engineered macrophage membrane-encapsulated nanospheres treatment with HGF-loaded gene (HGF@ETMM@NPS) group.

View Article and Find Full Text PDF

Background: Family history (FH) of psoriasis has been implicated as a risk factor for developing psoriasis. However, whether FH also carries information on clinical presentation and treatment response to biological agents in patients with psoriasis remains unclear.

Objective: This prospective, multicenter observational study aimed to analyze the clinical presentation and efficacy differences between patients with psoriasis with and without a FH.

View Article and Find Full Text PDF

MR-linac: role of artificial intelligence and automation.

Strahlenther Onkol

January 2025

Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Rämistrasse 100, 8091, Zurich, Switzerland.

The integration of artificial intelligence (AI) into radiotherapy has advanced significantly during the past 5 years, especially in terms of automating key processes like organ at risk delineation and treatment planning. These innovations have enhanced consistency, accuracy, and efficiency in clinical practice. Magnetic resonance (MR)-guided linear accelerators (MR-linacs) have greatly improved treatment accuracy and real-time plan adaptation, particularly for tumors near radiosensitive organs.

View Article and Find Full Text PDF

To research the value of Autostrain right ventricular (RV) technology in detecting and preventing right ventricular myocardial injury in patients undergoing breast cancer chemotherapy by providing an imaging basis for early identification. To examine the changes in various cardiac function parameters before and after chemotherapy, two-dimensional echocardiography was employed 48 h before chemotherapy, 48 h after the fourth cycle of chemotherapy, and 48 h after the eighth cycle of chemotherapy, respectively. The patients included those with breast cancer who underwent surgery and were primarily administered anthracycline-based chemotherapeutic drugs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!